Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1892 | 1-NM-PP1 | Potent tyrosine kinase inhibitor (TKI) of multiple targets (Src, Fyn, Abl, CDK, Trk) | €95.00 | |
| 2496 | 2,5-Dimethylcelecoxib | Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity | €75.00 | |
| 3957 | A-1155463 dihydrochloride | BH3 mimetic Ligand of BCL protein BCL-XL | Inquire | |
| 4008 | A-1210477 | Potent and selective inhibitor of MCL-1 | Inquire | |
| 3972 | A-1331852 | BH3 mimetic Ligand of BCL protein BCL-XL | €120.00 | |
| 1873 | Abiraterone | Inhibitor of CYP17A1 | €90.00 | |
| 1874 | Abiraterone acetate | Prodrug of Abiraterone; Inhibitor of CYP17A1 | €90.00 | |
| 2141 | ABT 199 | Potent, orally bioavailable BCL-2-selective inhibitor | €70.00 | |
| 3821 | ABT-263 | Potent, selective and orally bioavailable inhibitor of B-cell lymphoma-2 (BCL-2) family proteins | Inquire | |
| 1884 | Alectinib | Orally available and selective ALK inhibitor | €70.00 | |
| 3686 | AMG-176 | Potent and selective Mcl-1 inhibitor | €490.00 | |
| 1456 | AZD0530 difumarate | Inhibitor of SRC and ABL tyrosine kinases | €70.00 | |
| 2153 | AZD3463 | Potent inhibitor of ALK and IGF1R | €105.00 | |
| 3814 | AZD4320 | BH3-mimetic inhibitor of BCL-2 protein | Inquire | |
| 3731 | AZD5991 | BH3-Groove binding Mcl-1 inhibitor | Inquire | |
| 2185 | BAM 7 | Selective small-molecule activator of proapoptotic BAX | €90.00 | |
| 3714 | BCL-201 dihydrochloride | BH3-mimetic inhibitor of BCL-2 protein | Inquire | |
| 1828 | BH3I 1 | Inhibitor of Bcl-2 family protein | €125.00 | |
| 3047 | BI-6C9 | Inhibitor of BID protein | €145.00 | |
| 3295 | BIA | TMBIM6 antagonist | €120.00 | |
| 2978 | Brigatinib | Potent, selective, and orally active anaplastic lymphoma kinase (ALK) inhibitor | €80.00 | |
| 3431 | BTSA1 | Potent activator of proapoptotic BAX | €110.00 | |
| 3481 | BTYNB isomer | Ring-closed isomer of BTYNB | €110.00 | |
| 3931 | CEP-28122 | Highly potent, selective and orally active ALK inhibitor | Inquire | |
| 1863 | CID 5951923 | Inhibitor of Krüppel-like factor 5 (KLF5) | €135.00 | |
| 1654 | CP 100356 hydrochloride | P-gp inhibitor | €90.00 | |
| 2879 | CP 31398 | Stabilizer of p53 and inducer of apoptosis | €100.00 | |
| 3200 | DCLK1-IN-1 | Potent, selective and orally bioavailable DCLK1/2 inhibitor | €140.00 | |
| 3518 | DCZ0805 | NF-κB activation inhibitor | €130.00 | |
| 3766 | DT-2216 | Selective B-cell lymphoma-extra large (Bcl-XL) targeted protein degrader | Inquire | |